Herceptin biosimilar Herzuma now available in the USA

16 March 2020

Israel’s Teva Pharmaceutical Industries (NYSE: TEVA) and partner South Korea’s Celltrion Healthcare (Kosdaq: 091990) today announced that Herzuma (trastuzumab-pkrb) for Injection, a biosimilar to Roche’s blockbuster Herceptin, is now available in the USA with the same indications as the reference product including: adjuvant and metastatic breast cancer and metastatic gastric cancer.

In these indications, patients should be selected for therapy based on a US Food and Drug Administration-approved companion diagnostic for a trastuzumab product.

These adds to Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon (BSE: 532523) launch of Ogivri (trastuzumab-dkst) in the USA in December last year. Pfizer (NYSE: PFE) also launched its Herceptin biosimilar, Trazimera, earlier this year. Several other biosimilars have been approved by the FDA but not yet launched.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK